ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

AbbVie Gets Ireland’s Shire

by Ann M. Thayer
July 28, 2014 | APPEARED IN VOLUME 92, ISSUE 30

Illinois-based AbbVie has convinced the specialty pharmaceutical firm Shire to merge with it. AbbVie will pay about $54 billion in cash and stock to the Irish firm’s shareholders, who will own 25% of the combined company. The offer represents a 53% premium to Shire’s stock price in early May, when AbbVie first proposed a merger. It’s also 35% higher than AbbVie’s original offer. AbbVie was looking to diversify because more than half of its $19 billion in 2013 revenues came from the anti-inflammatory drug Humira, which loses patent protection in 2016. Major areas for the new firm will include immunology, rare diseases, neuroscience, metabolic diseases, hepatitis C, and oncology. The merger will also allow AbbVie to set up U.K. headquarters and lower its tax rate to about 13% from 22%. Lawmakers have responded negatively to such tax inversion moves by AbbVie and other U.S. companies. In May, legislators introduced bills in Congress after Pfizer attempted and failed to acquire London-based AstraZeneca. And U.S. Treasury Department Secretary Jacob J. Lew has asked House and Senate leaders to ban inversions retroactive to May. But policy analysts do not anticipate any legislative changes happening this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment